Saturday, 18 October 2014 17:14

Anticoagulation news items. Week commencing 13th October 2014

New product: Xarelto (rivaroxaban) 2.5 mg film-coated tablets

electronic Medicines Compendium
Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for prevention of atherothrombotic events in adult patients after an ACS with elevated cardiac biomarkers.

 

Guideline for the diagnosis and management of the rare coagulation disorders

British Journal of Haematology
This guideline covers the diagnosis and management of patients with rare coagulation disorders, defined as monogenic bleeding disorders caused by deficiency of a soluble coagulation factor or factors, other than von Willebrand disease, Haemophilia A or Haemophilia B.

 

dabigatran etexilate (Pradaxa)

Scottish Medicines Consortium
The SMC has accepted dabigatran etexilate (Pradaxa®) for use within NHS Scotland for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Cost-effectiveness of longer-term use (>18 months) is uncertain.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services